Chief Medical Editor's Page

By Ted E. Feldman, MD, FSCAI

New Frontiers in Transradial Intervention

A present-day assessment of three important clinical issues.

By Adhir Shroff, MD, MPH, FACC, FSCAI, and Sunil V. Rao, MD, FACC, FSCAI

Radial Catheter Selection

A guide to catheter selection for transradial coronary angiography and intervention.

By Nicholas R. Balaji, MD; Pinak B. Shah, MD; and Frederic S. Resnic, MD, MSc

Navigating Vasculature via the Radial Approach

Challenging anatomic variations that operators should plan to encounter during transradial interventions.

By Martial Hamon, MD, FESC

Avoiding and Managing Forearm Hematomas

Tips for managing this complication of transradial catheterization.

By Ronald P. Caputo, MD, FACC, FSCAI

Ultrasound Guidance for Radial Access

A step-by-step guide for ultrasound-facilitated radial cannulation.

By Alice Perlowski, MD; Michael H. Salinger, MD, FACC, FSCAI; Timothy McDonough, MD, FACC, FSCAI; and Ted E. Feldman, MD, FESC, FACC, FSCAI
Commentary by Ramon Quesada, MD, FACP, FACC, FSCAI

Bleeding Complications Associated With Transradial Versus Transfemoral Access

A review of the diminishing impact of bleeding with these two approaches and how the femoral route remains safe and viable in practice.

By Justin P. Levisay, MD, FACC, FSCAI, and Timothy A. Sanborn, MD, FACC, FSCAI

The RIVAL Trial

Timothy A. Sanborn, MD, FACC, FSCAI, and Kimberly A. Skelding, MD, FSCAI, discuss the recently published RIVAL trial data and the potential impact on which access sites operators will utilize for coronary imaging and interventions.

How does optical coherence tomography visualize coronary atherosclerotic lipid pool?

Sponsored by St. Jude Medical

By Maria D. Radu, MD; Lorenz Räber, MD; Patrick W. Serruys, MD, PhD; and Kari Saunamäki, MD, PhD

PFO in Cryptogenic Stroke Patients

The lead neurologist investigator from the REDUCE trial discusses his perspective on how cryptogenic stroke patients should be approached.
Featuring Scott Kasner, MD

Post-PCI Selection of Antithrombotic Therapy

Improvements in antithrombotic pharmacotherapy have led to important reductions in complications after percutaneous coronary intervention.

By John P. Vavalle, MD, and Robert A. Harrington, MD

Optimal Medical Therapy After PCI

Intensive multifactorial intervention to reduce cardiovascular risk.

By Matthew J. Sorrentino, MD, FACC

US INNOVATIONS

A preview of today's new products

An Interview With Brian Whisenant, MD

The Medical Director of Intermountain Medical Center's Structural Heart Disease Program discusses the significance of mitral regurgitation, advances in imaging, and the latest PFO trials that aim to determine the best devices and patient populations for closure.